Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is a fast-growing cancer where the bone marrow makes abnormal myeloblasts, red blood cells, or platelets. These "leukemia cells" quickly crowd out healthy cells, leading to a high risk of infection, anemia, and easy bleeding.
When You Should Consider AML Evaluation
Sudden bruising or tiny red spots on the skin called petechiae.
Shortness of breath and extreme pale skin indicating anemia.
Persistent fevers that do not respond to standard antibiotics.
Evidence of high risk for infection or unexplained, easy bleeding.
Methods of AML Classification
FLT3 Mutation: Found in about 30% of cases and usually requires specific targeted drugs.
IDH1/IDH2 Mutations: Subtypes targeted by newer oral therapies.
TP53 Mutation: Often indicates a more resistant form of the disease.
APL (Acute Promyelocytic Leukemia): A unique, highly curable subtype treated with non-chemo drugs like arsenic trioxide.
Secondary AML: Often found in older adults (60+) arising from previous blood disorders.
How AML Treatment Is Performed
Induction Therapy: Typically a "7+3" regimen involving 7 days of one chemotherapy and 3 days of another to achieve complete remission.
Consolidation (Post-remission): Additional chemotherapy or a Stem Cell Transplant to kill remaining microscopic cells.
Targeted Therapy: Use of specific drugs for mutations like FLT3 or IDH1/IDH2.
Low-Intensity Options: Use of Venetoclax pills or Hypomethylating Agents (HMA) like Azacitidine for patients who cannot handle high-dose chemo.
Non-Chemo Regimens: Use of All-Trans Retinoic Acid (ATRA) specifically for the APL subtype.
Pre-Procedure Preparation
Cytogenetic profiling to determine the specific genetic mutations and treatment plan.
Assessment of age and physical tolerance for intensive chemotherapy.
Evaluation of heart or kidney function to determine if low-intensity options like Venetoclax are necessary.
Screening for previous blood disorders that may lead to secondary AML.
Tests Before AML Treatment
Bone Marrow Analysis: To identify abnormal myeloblasts and clear the marrow of visible blasts.
Genetic Testing: To check for FLT3, IDH1/IDH2, or TP53 mutations.
Blood Counts: To assess the severity of anemia and low platelet levels.
Cytogenetic Profiling: To map the "cytogenetic" profile which dictates the specific therapy.
Life After AML Treatment
For younger adults (<60), the 5-year survival rate is roughly 40% to 50%.
For older adults (60+), survival is lower, typically around 10% to 20%.
Patients with the APL subtype enjoy an excellent cure rate of over 90%.
Ongoing monitoring is required during the consolidation phase to prevent a relapse.
Benefits of AML Treatment
Clears the blood and bone marrow of visible leukemia blasts.
Provides "insurance" against relapse through consolidation or transplants.
Offers improved survival for older patients through modern low-intensity pill combinations.
Restores the production of healthy white blood cells, red cells, and platelets.
